East Indian Sandalwood Oil (EISO) is an ideal candidate for development under FDA's botanical drug development guidelines, due to its long-standing use as a traditional medicine, its favorable safety profile, compositional and chemical stability, batch consistency and ease of formulation.

Rx Portfolio

A Unique Botanical Drug Substance: East Indian Sandalwood Oil (EISO) is a non-substitutable botanical drug candidate that is compositionally consistent, chemically stable and highly amenable to formulation as a dermatological product. Santalis has exclusive rights to the only sustainably-produced, ISO-compliant EISO that is produced under current Good Manufacturing Practices (cGMP) and has been accepted by the US FDA for use in advanced clinical trials.

Please contact us about partnering our proprietary range Rx programs.


OTC Portfolio

Santalis has developed a wide range of OTC products that exclusively contain Quintis’ East Indian Sandalwood Oil (EISO) and are formulated with US monograph drugs. These products include several that are ready for commercialization and are backed by clinical results and peer-reviewed publications.

Please contact us for information on partnering our proprietary range of OTC products.

Publications & Presentations

Take a look at Santalis’s recent publications and presentations that identify and support key clinical development activities.

Learn More